Zephyrnet Logo

Tag: RegDesk

MDCG Guidance on Clinical Investigations: Part 2 | EU

The new article highlights the aspects related to the existing regulatory pathway, the approach to be applied for different types and classes of medical...

FDA Draft Guidance on Additional Notifications Under Section 506J | FDA

The article provides an overview of the regulatory framework for additional notifications related to medical devices. Table of content The Food...

MDCG Guidance on Clinical Evaluation: Specific Aspects | MDCG

The new article highlights the aspects related to the content of the clinical investigation report, discusses additional considerations associated with the transitional period, and...

FDA Draft Guidance on Third Party Review Program: FDA Expectations | FDA

The article addresses the aspects related to the authority’s expectations associated with the respective program. Table of content The Food and...

TGA Guidance on Boundary and Combination Products: Boundary Products | TGA

The article highlights the key points related to the regulatory status of boundary products in Australia. Table of content The Therapeutic...

MDCG Guidance on Clinical Investigation: Timelines | MDCG

The new article highlights the aspects related to the timelines associated with the clinical investigations, the way they should be calculated, and other relevant...

FDA Draft Guidance on Third Party Review Program: Documentation and Reporting | United States

The new article describes in detail the approach to be applied concerning documenting the review process, its completion, and reporting. Table...

FDA Guidance on Notifying on Discontinuance or Interruption: Conditions | FDA

This article highlights the aspects related to the approach to be applied when determining whether a notification is required. Table of...

BfArM Guidance on Fast-Track Process for Digital Health Applications: Fees and Glossary | BfArM

The article addresses the aspects related to the fees payable by the interested parties and also provides definitions of the most important terms and...

CHMP Q&A Document on Development and Assessment for Companion Diagnostic Products | CHMP

The article highlights the key points associated with the regulatory framework for specific categories of medicinal products. Table of content ...

FDA Guidance on Discontinuance or Interruption Notification: Overview | United States

The article highlights the key points related to notification requirements medical device manufacturers should follow with respect to possible discontinuance or interruption in the...

FDA Guidance on Assessing the Credibility of Computational Modeling and Simulation: Factors, Goals, and Adequacy Assessment | FDA

The article describes in detail the approach to be applied for credibility factors and credibility goals to be considered by the parties responsible for...

Latest Intelligence

spot_img
spot_img